Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EBO-PEP

Financiado

Cerrado

The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis, preparedness and ef...

The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis, preparedness and efficacy evaluation during outbreak in Central and West-Africa. Ebola Virus Disease (EVD) outbreaks represent significant threats to public health and require effective countermeasures to minimize transmission and reduce mortality. The r-VSV-ZEBOV vaccine (Ervebo®) demonstrated efficacy in pro... ver más

31/05/2027

INSERM

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-24

HORIZON-JU-GH-EDCTP3-2023-01-04: Research to rapidly evaluate interv... ExpectedOutcome:This topic aims at supporting activities that are contributing to one or several of...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

INSERM

322.00K€ | Lider

MINISTERE DE L'ENSEIGNEMENT...

750.00K€ | Participante

FUNDACION PRIVADA INSTITUTO...

269.05K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VSV-EBOPLUS SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV... 15M€ Cerrado

EbolaVac Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zai... 22M€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

VSV-EBOVAC Vaccine safety and immunogenicity signatures of human respon... 5M€ Cerrado

EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterol... 51M€ Cerrado

PEVIA PAN EBOLA VACCINE INNOVATIVE APPROACH Sofia ref. 116088 18M€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2024-05-24
Fecha Fin: 2027-05-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ebola Virus Disease (EVD) outbreaks represent significant threats to public health and require effective countermeasures to minimize transmission and reduce mortality. The r-VSV-ZEBOV vaccine (Ervebo®) demonstrated efficacy in protecting contacts and contacts of contacts and has since been widely used in ring vaccination strategies in the Democratic Republic of Congo (DRC) outbreaks. However, its efficacy for high-risk contact is more and more debated. Furthermore, two monoclonal antibodies (mAbs), Ansuvimab (Ebanga®) and REGN-EB3 (Inmazeb®), have demonstrated their efficacy as treatment in reducing mortality in patients with EVD. With the availability of these management and prevention tools, the question of their use in Post-Exposure Prophylaxis (PEP), to protect individuals from contracting EVD after a high-risk contact, is more important than ever to effectively control EVD. The EBO-PEP consortium built on a highly successful collaboration between African and European institutions and NGOs. and allow to maintain a network for knowledge sharing and consortium collaboration to fight against EVD in Africa. The overall objective of the EBO-PEP project is to increase the portfolio of therapeutics tools against EVD, by evaluating a PEP strategy for high-risk contact. This will be accomplished through a multi-epidemic, multi-countries phase III clinical trial to test the efficacy of mAbs used as PEP during outbreak period. To address this objective, we focus our activities on 3 specific objectives: - to set up a multi-epidemic, multi-site and multi-countries phase III clinical trial in Africa to test the efficacy of mAbs used as PEP for EVD high-risk contact (EBO-PEP study), - to strengthen the capacities of clinical researchers and increase the knowledge and engagement of the community on EVD research, - to define the best PEP strategy for high-risk contact and to advocate for PEP implementation in the countries affected by EVD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores